A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women

Thorax

Volumn 60, Issue 8, 2005, Pages 623-628

  Lose, F ^b,c   Thompson, P J ^a,b,d   Duffy, D ^e   Stewart, G A ^b   Kedda, M A ^d  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Queensland Institute of Medical Research ^*  (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GELATINASE B; GLUTAMINE; ISOLEUCINE; PHENYLALANINE; PROLINE; SERINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; ASTHMA; AUSTRALIA; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; AUSTRALIA; FEMALE; FORCED EXPIRATORY VOLUME; HAPLOTYPES; HUMANS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, GENETIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 23744477293     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.026930     Document Type: Article

References (29)

1. Mautino G, Capony F, Bousquet J, et al. Balance in asthma between matrix metalloproteinases and their inhibitors. J Allergy Clin Immunol 1999;104:530-3.
2. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, et al. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem 1989;264:1353-6.
3. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945-50.
4. Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000;162:1157-61.
5. Cataldo DD, Bettiol J, Noel A, et al. Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 2002;122:1553-9.
6. Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998;102:783-8.
7. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94.
8. Pollanen PJ, Karhunen PJ, Mikkelsson J, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 2001;21:1446-50.
9. Minematsu N, Nakamura H, Tateno H, et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001;289:116-9.
10. Kedda AAA, Shi J, Duffy DL, et al. Characterisation of two polymorphisms in the LTC4 synthase gene in an Australian population of mild, moderate and severe asthmatics. J Allergy Clin Immunol 2004;113:889-95.
11. Australian National Asthma Council. Asthma management handbook. 2002. Available at http://www.nationalasthma.org.au/.
12. National Institutes of Health. Expert Panel Report II. Practical guide for the diagnosis and management of asthma. National Asthma Education and Prevention Program. NIH publication 99-4055A. Bethesda, MD: National Heart, Lung and Blood Institute, 1997.
13. R Development Core Team. R: A language and environment for statistical computing. 2003. Available at http://www.R-project.org.
14. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003;25:115-21.
15. Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-71.
16. Zhang B, Henney A, Eriksson P, et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 1999;105:418-23.
17. Wang X, Tromp G, Cole CW, et al. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol 1999;18:121-4.
18. Holla LI, Vasku A, Stejskalova A, et al. Functional polymorphism in the gelatinase B gene and asthma. Allergy 2000;55:900-1.
19. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992;90:41-54.
20. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002;3:285-98.
21. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995;248:496-510.
22. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000;25:106-10.
23. Colapietro P, Gervasini C, Natacci F, et al. NF1 exon 7 skipping and sequence alterations in exonic splice enhancers (ESEs) in a neurofibromatosis 1 patient. Hum Genet 2003;113:551-4.
24. Kramer F, Mohr N, Kellner U, et al. Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD). Hum Mutat 2003;22:418.
25. Cataldo DD, Tournoy KG, Vermaelen K, et al. Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol 2002;161:491-8.
26. Wenzel SE, Balzar S, Cundall M, et al. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003;111:1345-52.
27. Oshita Y, Koga T, Kamimura T, et al. Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax 2003;58:757-60.
28. Mottos W, Lim S, Russell R, et al. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 2002;122:1543-52.
29. Belleguic C, Corbel M, Germain N, et al. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 2002;32:217-23.